Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 4Completed 3Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 80Sarcoma 23Dermatologic 19Thoracic 7Lymphoid 5Endocrine 3Breast 3Tumor-Agnostic 2Other solid neoplasm 2Genitourinary 2Gastrointestinal 2Other hematologic neoplasm 1NET 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Temozolomide × Tumor-Agnostic × Clear all
NCT01284335 2019-01-10

A Safety Study in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
234 enrolled 23 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
104 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡